Our Pricing

Mounjaro vs Wegovy UK Results: Clinical Comparison by UK Pharmacists

Published on: June 03, 2026

Deciding between mounjaro vs wegovy uk results? Both injectable treatments are licensed by the MHRA for weight management, but they work through different mechanisms and deliver different clinical outcomes. At Cured Pharmacy, our UK-registered clinical team helps patients choose the right treatment based on their medical history, weight loss goals, and individual response to therapy.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that has been available in the UK since 2022 [2]. Semaglutide works by mimicking the natural GLP-1 hormone, which slows gastric emptying, reduces appetite, and improves blood sugar control. Both medications are administered as once-weekly subcutaneous injections, but their different receptor targets lead to distinct clinical profiles.

The dual-action mechanism of tirzepatide may explain why clinical trials have shown greater average weight reduction compared to semaglutide-based treatments, though individual responses vary significantly [1][3].

Mounjaro vs Wegovy UK Results: Clinical Trial Data

In the SURMOUNT-1 trial, participants taking the highest licensed dose of Mounjaro (15mg) achieved an average body weight reduction of 22.5% over 72 weeks [1]. This represents approximately 52 pounds of weight loss for a person starting at 230 pounds, though individual results varied considerably based on adherence, lifestyle factors, and metabolic response.

The STEP 1 trial evaluated Wegovy in adults with obesity, showing an average weight reduction of 14.9% over 68 weeks at the 2.4mg maintenance dose [2]. Participants also experienced improvements in cardiovascular risk markers, including blood pressure and cholesterol levels, which contributed to Wegovy's subsequent approval for cardiovascular risk reduction.

Direct head-to-head trials comparing tirzepatide and semaglutide at their respective weight management doses have shown that tirzepatide users experienced significantly greater weight reduction on average [3]. However, both medications demonstrated superior efficacy compared to placebo and lifestyle intervention alone, and both are considered clinically effective options by NICE guidance.

Real-World UK Patient Outcomes

Clinical trial results reflect controlled research conditions, but real-world outcomes depend on multiple factors including treatment adherence, dietary modifications, physical activity levels, and individual metabolic differences. At Cured Pharmacy, our clinical team monitors patient progress and adjusts treatment plans based on individual response, tolerability, and weight loss trajectory.

Some patients achieve optimal results with Wegovy and experience minimal side effects, while others may benefit from Mounjaro's dual-receptor mechanism. Your UK prescriber will consider your medical history, previous weight loss attempts, budget considerations, and any contraindications when recommending the most appropriate treatment option.

Side Effects: Mounjaro vs Wegovy Comparison

Both medications belong to the incretin mimetic class and share similar gastrointestinal side effect profiles, as they slow gastric emptying and affect digestive function [1][2]. The most commonly reported side effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases.

Clinical trials showed that gastrointestinal side effects were generally mild to moderate in severity and decreased over time as patients adapted to treatment [1][2]. Starting at lower doses and gradually increasing according to the licensed titration schedule helps minimise these effects. Most patients find that side effects improve significantly after the first 4-8 weeks of treatment.

Serious side effects are rare but can include pancreatitis, gallbladder problems, and severe allergic reactions. Both medications carry warnings about thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [4]. Your UK prescriber will review your complete medical history to identify any contraindications before prescribing either treatment.

Managing Side Effects Effectively

Our clinical team at Cured Pharmacy provides detailed guidance on managing common side effects, including dietary modifications, hydration strategies, and timing of injections. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce gastrointestinal discomfort during the initial treatment phases.

If you experience persistent or severe side effects, your prescriber may adjust your dose escalation schedule or consider switching to an alternative treatment. Never discontinue prescription medication without consulting your healthcare provider, as abrupt cessation can affect your weight management progress.

Dosing Schedules and Treatment Duration

Mounjaro follows a structured dose escalation schedule starting at 2.5mg once weekly for four weeks, then increasing to 5mg, 7.5mg, 10mg, 12.5mg, and up to a maximum maintenance dose of 15mg based on individual response and tolerability [1]. This gradual titration helps minimise gastrointestinal side effects whilst allowing your body to adapt to the medication.

Wegovy starts at 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg [2]. The slower titration schedule spans approximately 16-20 weeks before reaching the full therapeutic dose, compared to Mounjaro's 20-24 week escalation to maximum dosing.

Both treatments are intended for long-term use as part of a comprehensive weight management programme that includes dietary modifications and increased physical activity. Clinical trials evaluated treatment duration of 68-72 weeks, and many patients continue therapy beyond this period under ongoing medical supervision to maintain weight loss results [1][2].

Cost Comparison: Mounjaro vs Wegovy UK Pricing

At Cured Pharmacy, Mounjaro is available from £124.99 per month, making it accessible for UK patients seeking this advanced dual-receptor treatment. Transparent upfront pricing means you'll see the exact cost before completing your free clinical consultation, with no hidden fees or surprise charges.

Wegovy pricing varies by dose, with competitive rates across the UK market. Both medications represent a significant investment in your health, and many patients find that the clinical benefits, including improved metabolic markers and reduced cardiovascular risk, justify the ongoing cost when combined with lifestyle modifications.

Your final prescription cost depends on the dose your UK prescriber determines is appropriate based on your clinical assessment, current weight, medical history, and treatment goals. All prices at Cured Pharmacy include the medication, clinical consultation, and discreet delivery to your preferred UK address.

Value Considerations Beyond Price

When comparing costs, consider the total value proposition including clinical support, convenience, and treatment outcomes. At Cured Pharmacy, you receive ongoing access to UK-registered prescribers, discreet packaging, and genuine UK-licensed medications dispensed by our superintendent pharmacist Tarun Kumar (GPhC 2233073).

Some patients achieve their weight loss goals more quickly with one medication versus another, which can affect the total treatment cost over time. Your prescriber will discuss realistic timelines and expected outcomes during your consultation to help you make an informed decision about which treatment offers the best value for your individual circumstances.

Which Treatment Is Right for You?

Choosing between Mounjaro and Wegovy depends on multiple clinical factors including your BMI, weight loss goals, medical history, previous treatment responses, budget, and personal preferences regarding side effect profiles. There is no universally "better" option—the optimal choice varies by individual patient circumstances.

Mounjaro may be particularly suitable for patients seeking maximum weight reduction based on clinical trial data, those who have not achieved adequate results with single-pathway GLP-1 treatments, or individuals who tolerate the dual-receptor mechanism well [1][3]. The higher average weight loss percentages observed in trials make it an attractive option for patients with significant weight to lose.

Wegovy remains an excellent choice for many patients, particularly those who respond well to GLP-1 therapy, prefer a medication with extensive real-world safety data, or are managing cardiovascular risk factors alongside weight management [2]. The established track record and slightly lower starting price point make it accessible for a broad range of patients.

At Cured Pharmacy, your free online consultation takes under three minutes and connects you with UK-registered prescribers who will assess your complete medical profile, discuss your treatment preferences, and recommend the most appropriate option. Both medications require ongoing medical supervision, and your prescriber will monitor your progress through regular follow-up assessments.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Glucagon-like peptide-1 (GLP-1) receptor agonists: Reports of thyroid cancer. Drug Safety Update, 16(9). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, lifestyle modifications, and metabolic response.